- |||||||||| lacosamide / Generic mfg.
Journal: Lacosamide and pregnancy: Data from spontaneous and solicited reports. (Pubmed Central) - Feb 27, 2024 Most pregnancies with LCM exposure resulted in healthy live births, and no new safety issues were identified. These findings should be interpreted with caution, as additional data are needed to fully evaluate the safety profile of LCM in pregnancy.
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma
Review, Journal, Metastases: Antiepileptic Strategies for Patients with Primary and Metastatic Brain Tumors. (Pubmed Central) - Feb 27, 2024 The consensus among most Neuro-Oncology providers is to initiate levetiracetam monotherapy after a first seizure in a brain tumor patient, as long as the patient does not have any psychiatric co-morbidities. If levetiracetam is not tolerated well or is ineffective, other appropriate initial AED options for monotherapy or as an add-on anticonvulsant include lacosamide, valproic acid, briviracetam, lamotrigine, and perampanel.
- |||||||||| rufinamide / Generic mfg.
Journal: Inhibition of resurgent Na currents by rufinamide. (Pubmed Central) - Feb 26, 2024 The modest but correlative inhibition of both currents may make a novel synergistic effect and thus strong-enough suppression of pathological repetitive and especially burst discharges. Rufinamide may thus have a unique spectrum of therapeutic applications for disorders with excessive neural excitabilities.
- |||||||||| levetiracetam / Generic mfg.
Levetiracetam-associated Rhabdomyolysis (San Diego Convention Center, Area K (Hall H, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_6040; He received multiple doses of lorazepam and required intubation for airway protection...Levetiracetam was discontinued and changed to lacosamide...The adverse event of rhabdomyolysis following levetiracetam administration remains rare. When evaluating a patient with rhabdomyolysis special attention needs to be paid to history and physical examination as well as medications administered.
- |||||||||| Xcopri (cenobamate) / SK Bio, Angelini Group, Endo
New Onset Refractory Status Epilepticus in Prion Disease (San Diego Convention Center, Area E (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_5949; There is minimal guidance in the literature on medications to treat RSE. Currently, the patient's autopsy is pending at a National Prion Disease Pathology Surveillance Center.
- |||||||||| Novel Use of Mini Convex EBUS Bronchoscope for Diagnosis and Staging of Thymic Neoplasms (San Diego Convention Center, Area C (Hall A-B2, Ground Level)) - Feb 20, 2024 - Abstract #ATS2024ATS_1469;
Levetiracetam was changed to lacosamide and clobazam for seizure prevention...Per oncology, the patient began chemotherapy with a 3-day course of cisplatin/doxorubicin/cyclophosphamide on day 16 with methylprednisolone, followed by IVIg...However, this comes with increased risk of complications given it is an open procedure. This case shows the possibility of using mini convex EBUS bronchoscopy as a less invasive option that could potentially reduce complications and improve patient outcomes.
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Journal, Real-world evidence, Real-world: A real-world comparison among third-generation antiseizure medications: results from the COMPARE study. (Pubmed Central) - Feb 14, 2024 Rashes are more likely to occur when multiple antiseizure medicines are used simultaneously, typically within 10 days of treatment initiation. Comparative evidence from real-world studies may help clinicians to tailor treatments according to patients' demographic and clinical characteristics.
- |||||||||| lacosamide / Generic mfg.
Journal, Video: Pitfalls of using video-EEG for a trial endpoint in children aged <4?years with focal seizures. (Pubmed Central) - Feb 6, 2024 P3 High inter-reader variability and low inter-reader reliability of the interpretation of seizure types and counts prevent confident conclusion regarding the lack of efficacy of lacosamide in this population. We recommend studies in very young children do not employ video-EEGs exclusively for accurate study inclusion or as an efficacy measure.
- |||||||||| lacosamide / Generic mfg.
Journal: Case 321: Leigh Syndrome. (Pubmed Central) - Jan 30, 2024 The patient was subsequently started on lacosamide...There was no history of travel, recent infection, or vaccine administration. MRI of the brain with spectroscopy was performed for further evaluation.
- |||||||||| lacosamide / Generic mfg.
LACOSAMIDE INDUCED COMPLETE HEART BLOCK IN A YOUNG FEMALE (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_3717; We describe the youngest case of LCM induced complete heart block, ever reported.Case: A 33-year-old female with refractory epilepsy (maintained on lamotrigine, levetiracetam, LCM), cerebral palsy, and intellectual disability presented after a fall resulting in a left spiral tibial shaft fracture. The severity of LCM associated conduction abnormality highlights the importance of close monitoring of these patients.
- |||||||||| lacosamide / Generic mfg.
TRANSIENT LEFT BUNDLE BRANCH BLOCK AND ORGANIZATION OF ATRIAL FIBRILLATION TO ATRIAL FLUTTER WITH LACOSAMIDE INFUSION (Hall B4-5) - Jan 26, 2024 - Abstract #ACC2024ACC_333; He underwent emergent decompressive hemicraniotomy for SDH evacuation, and levetiracetam was initiated for seizure prophylaxis...Lacosamide was held, resulting in resolution of LBBB and reversion of atrial rhythm to atrial fibrillation.Decision?making: Conduction system abnormalities, including bundle branch blocks, PR/QT prolongation and ventricular tachycardia (VT) are known side effects of the Class Ic antiarrhythmic agent flecainide, mediated via sodium channel blockade. Lacosamide may induce new bundle branch blocks and organization of AF to AFL; cessation of the medication and monitoring with serial EKGs results in resolution of these changes.
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma, Xcopri (cenobamate) / SK Bio, Angelini Group, Endo, Aptiom (eslicarbazepine) / Sumitomo Pharma, BIAL
Clinical, Retrospective data, Review: The efficacy and safety of third-generation antiseizure medications and non-invasive brain stimulation to treat refractory epilepsy: a systematic review and network meta-analysis study. (Pubmed Central) - Jan 24, 2024 Although rTMS and tDCS did not reduce seizure frequency as effectively as the five drugs, their safety was confirmed. PROSPERO, https://www.crd.york.ac.uk/prospero/ (CRD42023441097).
- |||||||||| Fycompa (perampanel) / Eisai, Catalyst Pharma
Trial completion date, Trial primary completion date: SUPER-CAT: Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest (clinicaltrials.gov) - Jan 1, 2024 P=N/A, N=80, Recruiting, Instead, individual reference values should be established when sufficient clinical data are available, in line with the ILAE position paper, 2008, TDM. Trial completion date: Oct 2023 --> Sep 2024 | Trial primary completion date: Oct 2023 --> Jun 2024
- |||||||||| Review, Journal: Status epilepticus in the ICU. (Pubmed Central) - Dec 20, 2023
Initial management consists of rapid administration of benzodiazepines and one of the following non-sedating intravenous antiseizure medications (ASM): (fos-)phenytoin, levetiracetam, or valproate; other ASM are increasingly used, such as lacosamide or brivaracetam...At this step, management may include non-sedating or sedating compounds including ketamine and barbiturates...Short-term mortality ranges from 10 to 15% after SE and is primarily related to increasing age, underlying etiology, and medical comorbidities. Refractoriness of treatment is clearly related to outcome with mortality rising from 10% in responsive cases, to 25% in refractory, and nearly 40% in super-refractory SE.
- |||||||||| Journal: Simple HPLC-UV Method for Therapeutic Drug Monitoring of 12 Antiepileptic Drugs and Their Main Metabolites in Human Plasma. (Pubmed Central) - Dec 9, 2023
It showed to be selective, accurate, precise, and linear over the concentration ranges of 1-50 mg/L for phenobarbital, phenytoin, levetiracetam, rufinamide, zonisamide, and lacosamide; 0.5-50 mg/L for lamotrigine, primidone, carbamazepine and 10-monohydroxycarbazepine; 0.2-10 mg/L for carbamazepine metabolites: 10,11-trans-dihydroxy-10,11-dihydrocarbamazepine and carbamazepine-10,11-epoxide; 0.1-10 mg/L for oxcarbazepine; 2-100 mg/L for felbamate and 3-150 mg/L for ethosuximide. The suitability of the validated method for routine therapeutic drug monitoring was confirmed by quantification of the analytes in plasma samples from patients with epilepsy on combination antiepileptic therapy.
- |||||||||| Review, Journal, Adverse events: Priapism associated with anti-seizure medications: a pharmacovigilance study and a review of published cases. (Pubmed Central) - Dec 8, 2023
We also found published cases of priapism for pregabalin and phenytoin in the literature and FAERS, and at least one reported adverse event of priapism in FAERS for clonazepam, lacosamide, ethosuximide, oxcarbazepine and vigabatrin in which they were considered primary suspect. Our study identified signals for priapism for several anti-seizure medications, but these results need to be confirmed in well-designed pharmacoepidemiological studies.
- |||||||||| Journal: Turbulent Flow Liquid Chromatography-Tandem Mass Spectrometry Methods for Antiepileptic Drug Quantitation in Serum. (Pubmed Central) - Dec 5, 2023
TFC-MS/MS testing was performed using a TLX-2 online sample preparation liquid chromatography (SPLC) system coupled to an API 5500 Q-Trap tandem mass spectrometer. Quantification of 10,11-dihydro-10-hydroxycarbamazepine, lacosamide, lamotrigine, levetiracetam, rufinamide, topiramate, and zonisamide was, respectively, performed using calibration curves (2-60
- |||||||||| lacosamide / Generic mfg., propranolol / Generic mfg.
Trial initiation date: Lacosamide Versus Propranolol in Migraine (clinicaltrials.gov) - Nov 29, 2023 P3, N=600, Completed, The linear assay ranges were 0.3-26 Initiation date: Jan 2022 --> Jun 2022
- |||||||||| lacosamide / Generic mfg.
Journal: Neonatal Cardiac Arrest Following Lacosamide Treatment: A Case Report. (Pubmed Central) - Nov 21, 2023 This is the first report of adverse cardiac event (AV block) in the setting of neonatal lacosamide use. Risk of future adverse cardiac events should be evaluated when determining the safety and efficacy of lacosamide in the neonatal population.
- |||||||||| lacosamide / Generic mfg., atorvastatin / Generic mfg., levetiracetam / Generic mfg.
PK/PD data, Preclinical, Journal: Differential Pharmacokinetic Interplay of Atorvastatin on Lacosamide and Levetiracetam on Experimental Convulsions in Mice. (Pubmed Central) - Nov 5, 2023 This study has demonstrated that the plasma concentration of ATOR was potentiated in the presence of LACO, but not in the presence of LEVE and it has provided significant protection against both the electro and chemo-convulsive models in mice. This could be due to the symbiotic pharmacokinetic interplay of ATOR with LACO, and possibly, this interplay may interfere with sodium channel conductance.
- |||||||||| lacosamide / Generic mfg., oxcarbazepine / Generic mfg.
Journal: Analysis of the efficacy and influencing factors of sodium channel blockers in the treatment of focal epilepsy in infants under 6 months of age (Pubmed Central) - Oct 29, 2023 There were 9 cases of rash, which subsided in 6 cases after discontinuing oxcarbazepine and switching to lacosamide, and 7 cases of electrocardiogram abnormalities, which improved after withdrawing oxcarbazepine and changing to lacosamide in 1 case. SCB are effective and tolerable in the treatment of focal epilepsy in infants under 6 months of age, with better efficacy in patients with genetic variants of the sodium or potassium channel, focal seizures only, and seizure onset >3-6 months of age.
|